14 July 2020 

Pfizer and BioNTech have received fast track designation from the US Food and Drug Administration (FDA) for two of their four potential Covid-19 vaccines. The designation is based on preliminary results from ongoing Phase I/II studies in the US and Germany, and also data from animal immunogenicity studies.

Swiss contract drug manufacturer Lonza Group has licensed its technology to China-based Junshi Biosciences for the production of a neutralising antibody against Covid-19. Lonza noted that the neutralising antibody was developed using its gene expression system, GS Xceed. The antibody is currently in clinical trials in China.

India-based Glenmark Pharmaceuticals has lowered the price of its Covid-19 drug, FabiFlu, to INR 75 ($0.99) per tablet. The drug, a generic version of favipiravir, was earlier sold at INR 103 ($1.37) per tablet to treat patients with mild-to-moderate Covid-19 symptoms. The company expects the price reduction to enable better access to its drug for patients across India.

Tonix Pharmaceuticals has entered into a new preclinical research and option agreement with Kansas State University for the development of a Covid-19 vaccine candidate using a live virus vaccine vector platform and the CD40-ligand. Under the partnership, the university will be responsible for preclinical development of a live replicating virus vaccine against Covid-19 based on bovine parainfluenza virus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.